Merck’s Plan of a P2X3 Pipeline Lifts Bellus
Insights - Last week, Bellus (BLUSF) rallied from $1.50 range to over $2.00, touching a high of $2.31. This all happened on heavy volume. Remember, we first … Continue Reading
Read nowAuthor Archives: D Mero
Late 2019 Data Could Position Gene Therapy Company As Leading Candidate in Wet AMD
Insights - Adverum (ADVM) has rallied year to date from $3.50 to $10/share as the market is picking up on the gene therapy story. With data in … Continue Reading
Premium
Acer’s Clinically Relevant Data Could Be Enough For Desperate Patient Population
Insights - Acer Therapeutics (ACER) has a PDUFA date on June 25, 2019 for the treatment of vascular Ehlers-Danlos syndrome (“vEDS”). vEDS is a serious rare disease … Continue Reading
Premium
With Completion of Spring Bank’s (SBPH) ACHIEVE, All Eyes on Gilead’s Combination Data
Insights - Spring Bank (SBPH) presented data for their Phase 2 ACHIEVE trial at EASL conference today, including their 200mg cohort. Data was in line with expectations and confirms … Continue Reading
Read now
Aldeyra’s Allergic Conjunctivitis Data Positions Candidate Well in Dry Eye Disease
Insights - This morning Aldeyra released topline data for their Phase 3 candidate reproxalap in allergic conjunctivitis. The company showed statistical significance in both primary and secondary endpoints Primary … Continue Reading
Read nowMarket Overlooking Eventful Upcoming 12 Months for Spring Bank (SBPH)
Insights - Spring Bank provided a business update earlier this week to discuss 2019 development plant for their immune-modulator inarigivir in treating Hepatitis B. Although the company also discussed … Continue Reading
Premium
Fennec Delays NDA Due to Manufacturing Facility Change
Insights - Fennec announced some bad news this morning. Their NDA submission for Pedmark has been pushed back by 9-12 months to “late 2019 to early 2020”. The NDA … Continue Reading
Read now